secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2026-07-15T20:05:37+00:00
Accession:  0001649094-26-000030
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte director Heath Lukatch retires; John Markels appointed to board
-----------------------------------------------------------------------

- Heath Lukatch retired from Vaxcyte board effective July 16, 2026; no disagreement with company.
- John Markels appointed as Class II director, term expiring at 2028 annual meeting.
- Markels will serve on Audit and Compensation committees; qualifies as independent under Nasdaq rules.
- Markels receives standard non-employee director compensation; annual equity grant currently $430,000.
- No transactions or arrangements between Markels and company requiring disclosure under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/0001649094-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/pcvx-20260713.htm
  HTML page:      https://secwatch.observer/filing/0001649094-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer